Bavarian Nordic A/S
BAVA
주식 순위
#5046
Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in... Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine. Bavarian Nordic also maintains a robust pipeline of investigational treatments. This includes MVA-BN (freeze-dried), which has successfully completed Phase III clinical trials for smallpox; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, which completed Phase II trials targeting SARS-CoV-2; and TAEK-VAC, presently in Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The firm engages in key partnerships, notably a license and collaboration agreement with AdaptVac, and licensing agreements with both the National Cancer Institute and the Public Health Service. Bavarian Nordic operates across a wide international footprint, with a presence in countries such as the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and numerous other global markets.
주가
$37.76
마지막 동기화: 2026-10-16
시가총액
$2.87B
변동 (1일)
-0.17%
변동 (1년)
1.44%
국가
DK
거래 Bavarian Nordic A/S (BAVA)
카테고리
Healthcare
의 시가총액 Bavarian Nordic A/S(BAVA)
시가총액: $2.87B
October 2026 기준으로 Bavarian Nordic A/S의 시가총액은 $2.87B입니다. 이는 당사 데이터에 따르면 Bavarian Nordic A/S이 세계에서 5046th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2003부터 2026까지 Bavarian Nordic A/S의 시가총액 기록
